奥曲肽注射液联合静脉滴注乌司他丁治疗急性胰腺炎患者的疗效

Octreotide injection combined with intravenous ulinastatin for treatment of acute pancreatitis: A controlled study

目的:探讨临床中乌司他丁与奥曲肽联合治疗急性胰腺炎(acute pancreatitis,AP)的临床疗效.方法:选取石河子大学医学院第一附属医院2012-01/2013-12期间的110例AP患者为研究对象,将其按照随机数字法分为联合组与对照组,对照组给予奥曲肽治疗,联合组给予乌司他丁与奥曲肽联合治疗,观察两组临床效果.结果:联合组治疗总有效率与对照组比较差异有统计学意义(92.7%vs 74.5%,P<0.05);联合组腹痛与腹胀改善时间、尿淀粉酶恢复时间、住院时间vs对照组(t=6.025,7.381,9.184,均P<0.05).治疗前联合组与对照组肿瘤坏死因子-α、白介素-15(interleukin-15,I L-15)、I L-10、C反应蛋白比较差异无统计学意义(P>0.05);治疗后组间的数据比较差异有统计学意义(P<0.05).结论:临床中对于AP患者应用乌司他丁与奥曲肽联合治疗效果显著,能够提高患者治疗有效率,并且改善临床症状,值得临床中应用.

AIM： To evaluate the clinical efficacy of ulina- statin combined with octreotide in the treatment of acute pancreatitis （AP）. METHODS： One hundred and ten AP patients treated at our hospital from January 2012 to De- cember 2013 were randomized into either a com- bination group or a control group. The control group received octreotide alone, while the com- bination group was given ulinastatin and octreo- tide. Clinical effects were compared between the two groups. RESULTS： The total effective rate was signifi-cantly higher in the combination group than in the control group （74.5% vs 92.7%, P 〈 0.05）. Abdominal pain and bloating, time to urine amylase recovery and hospital stay were im- proved more significantly in the combination group than in the control group （t = 6.025, 7.381, 9.184, P 〈 0.05 for all）. Serum levels of tumor ne- crosis factor-m, interleukin-15 （IL-15）, IL-10, and C-reactive protein did not differ significantly be- tween the two groups before treatment （P 〉 0.05）, but were statistically different after treatment （P 〈 0.05 for all）. CONCLUSION： Ulinastatin combined with -αtreotide has significant clinical effects and can significantly improve clinical symptoms in AP patients.